Nisa Investment Advisors LLC Sells 4,559 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Nisa Investment Advisors LLC lessened its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 77.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,291 shares of the medical device company’s stock after selling 4,559 shares during the period. Nisa Investment Advisors LLC’s holdings in Tandem Diabetes Care were worth $47,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the business. Brooklyn Investment Group acquired a new position in shares of Tandem Diabetes Care in the third quarter valued at $28,000. Assetmark Inc. bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter worth about $29,000. ORG Wealth Partners LLC acquired a new position in Tandem Diabetes Care in the 3rd quarter valued at about $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Tandem Diabetes Care by 4.7% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,664 shares of the medical device company’s stock valued at $664,000 after acquiring an additional 704 shares during the period. Finally, Hanseatic Management Services Inc. lifted its position in Tandem Diabetes Care by 5.4% during the third quarter. Hanseatic Management Services Inc. now owns 13,941 shares of the medical device company’s stock worth $591,000 after acquiring an additional 710 shares during the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently commented on TNDM shares. Sanford C. Bernstein initiated coverage on Tandem Diabetes Care in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $42.00 target price on the stock. The Goldman Sachs Group began coverage on Tandem Diabetes Care in a report on Friday, October 4th. They issued a “neutral” rating and a $46.00 price objective on the stock. Citigroup dropped their target price on Tandem Diabetes Care from $57.00 to $50.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Canaccord Genuity Group decreased their price target on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Finally, Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 price objective for the company in a research note on Monday, December 2nd. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.81.

Tandem Diabetes Care Trading Up 0.1 %

Shares of TNDM stock opened at $37.06 on Friday. Tandem Diabetes Care, Inc. has a fifty-two week low of $21.85 and a fifty-two week high of $53.69. The stock’s fifty day moving average price is $34.85 and its two-hundred day moving average price is $37.49. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company has a market cap of $2.43 billion, a PE ratio of -19.20 and a beta of 1.29.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.08. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business had revenue of $243.97 million for the quarter, compared to analyst estimates of $224.14 million. During the same period last year, the firm posted ($0.38) earnings per share. Tandem Diabetes Care’s revenue was up 31.4% compared to the same quarter last year. Equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Insider Activity

In related news, Director Kim D. Blickenstaff sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the director now owns 195,190 shares of the company’s stock, valued at $5,855,700. This represents a 4.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.20% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.